BRPI0410023A - processo para preparação de um fator quimiotáctico modificado de modo n-terminal - Google Patents

processo para preparação de um fator quimiotáctico modificado de modo n-terminal

Info

Publication number
BRPI0410023A
BRPI0410023A BRPI0410023-9A BRPI0410023A BRPI0410023A BR PI0410023 A BRPI0410023 A BR PI0410023A BR PI0410023 A BRPI0410023 A BR PI0410023A BR PI0410023 A BRPI0410023 A BR PI0410023A
Authority
BR
Brazil
Prior art keywords
mcp
preparing
monocytes
agonist
chemotactic factor
Prior art date
Application number
BRPI0410023-9A
Other languages
English (en)
Inventor
Robert Wandl
Roman Necina
Randolph Seidler
Martin Lenter
Henri Doods
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BRPI0410023A publication Critical patent/BRPI0410023A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"PROCESSO PARA PREPARAçãO DE UM FATOR QUIMIOTáCTICO MODIFICADO DE MODO N-TERMINAL". A presente invenção refere-se a um processo para preparação de pyroGlu-MCP-1 a partir de Gln-MCP-1 preparado de modo recombinante, no qual o Gln-MCP-1 é incubado a uma temperatura na faixa de 30<198>C e 80<198>C, em uma solução tampão com uma concentração de sal na faixa de 10 mM e valor de pH na faixa de 2 até 7,5, até que pelo menos 90% do MCP-1 esteja presente em forma do pyroGlu-MCP-1.
BRPI0410023-9A 2003-05-02 2004-04-13 processo para preparação de um fator quimiotáctico modificado de modo n-terminal BRPI0410023A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03010014A EP1473304A1 (de) 2003-05-02 2003-05-02 Verfahren zur Herstellung eines N-terminal modifizierten chemotaktischen Faktors
PCT/EP2004/003856 WO2004096850A1 (de) 2003-05-02 2004-04-13 Verfahren zur herstellung eines n-terminal modifizierten chemotaktischen faktors

Publications (1)

Publication Number Publication Date
BRPI0410023A true BRPI0410023A (pt) 2006-04-25

Family

ID=32981800

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410023-9A BRPI0410023A (pt) 2003-05-02 2004-04-13 processo para preparação de um fator quimiotáctico modificado de modo n-terminal

Country Status (20)

Country Link
EP (2) EP1473304A1 (pt)
JP (1) JP2007535891A (pt)
KR (1) KR20050121751A (pt)
CN (1) CN1784420A (pt)
AT (1) ATE398631T1 (pt)
AU (1) AU2004233964A1 (pt)
BR (1) BRPI0410023A (pt)
CA (1) CA2524270A1 (pt)
CO (1) CO5640145A2 (pt)
DE (1) DE502004007394D1 (pt)
DK (1) DK1622936T3 (pt)
ES (1) ES2309528T3 (pt)
MX (1) MXPA05011700A (pt)
PL (1) PL1622936T3 (pt)
PT (1) PT1622936E (pt)
RU (1) RU2005137356A (pt)
SI (1) SI1622936T1 (pt)
UA (1) UA83661C2 (pt)
WO (1) WO2004096850A1 (pt)
ZA (1) ZA200507702B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008002101A (es) 2005-08-12 2008-04-19 Schering Corp Fusiones de la proteina-1 quimiotactica de monocito.
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92937A0 (en) * 1989-01-31 1990-09-17 Us Health Human derived monocyte attracting protein,pharmaceutical compositions comprising it and dna encoding it
US6869924B1 (en) * 1989-01-31 2005-03-22 The United States Of America As Represented By The Department Of Health And Human Services Human derived monocyte attracting purified protein product useful in a method of treating infection and neoplasms in a human body, and the cloning of full length cDNA thereof
WO1999005279A1 (en) * 1997-07-25 1999-02-04 Zeneca Limited Mcp-1 analogs

Also Published As

Publication number Publication date
EP1622936A1 (de) 2006-02-08
DE502004007394D1 (de) 2008-07-31
PT1622936E (pt) 2008-08-08
UA83661C2 (ru) 2008-08-11
ATE398631T1 (de) 2008-07-15
SI1622936T1 (sl) 2008-12-31
EP1473304A1 (de) 2004-11-03
RU2005137356A (ru) 2006-06-10
CA2524270A1 (en) 2004-11-11
ES2309528T3 (es) 2008-12-16
ZA200507702B (en) 2007-02-28
MXPA05011700A (es) 2006-01-23
AU2004233964A1 (en) 2004-11-11
CO5640145A2 (es) 2006-05-31
EP1622936B1 (de) 2008-06-18
WO2004096850A1 (de) 2004-11-11
JP2007535891A (ja) 2007-12-13
KR20050121751A (ko) 2005-12-27
CN1784420A (zh) 2006-06-07
PL1622936T3 (pl) 2008-11-28
DK1622936T3 (da) 2008-10-27

Similar Documents

Publication Publication Date Title
Eble et al. α2β1 integrin is not recognized by rhodocytin but is the specific, high affinity target of rhodocetin, an RGD-independent disintegrin and potent inhibitor of cell adhesion to collagen
Mochizuki et al. IL-4 induces eotaxin: a possible mechanism of selective eosinophil recruitment in helminth infection and atopy
Utani et al. A unique sequence of the laminin α3 G domain binds to heparin and promotes cell adhesion through syndecan-2 and-4
Renné et al. High molecular weight kininogen utilizes heparan sulfate proteoglycans for accumulation on endothelial cells
Konttinen et al. Increased expression of extracellular matrix metalloproteinase inducer in rheumatoid synovium
Herwald et al. Isolation and characterization of the kininogen-binding protein p33 from endothelial cells: identity with the gC1q receptor
Bianco et al. Expression of bone sialoprotein (BSP) in developing human tissues
Ten Hagen et al. Cloning and characterization of a ninth member of the UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase family, ppGaNTase-T9
Israel et al. Expression and characterization of bone morphogenetic protein-2 in Chinese hamster ovary cells
Greaves et al. Molecular features of CD34: a hemopoietic progenitor cell-associated molecule
Jensen et al. Fibrinogen and fibrin induce synthesis of proinflammatory cytokines from isolated peripheral blood mononuclear cells
US5759533A (en) Neutrophil-activating peptide-2
US5993814A (en) Agents for inhibition of chemoattractant
PT813541E (pt) Processo de producao de uma proteina
MX2007009466A (es) Anticuerpos monoclonales de anti-interferon alfa y metodos para su uso.
BRPI0411650A (pt) variante polipeptìdica do fator vii (fvii) ou do fator viia (fviia), sequencia de nucleotìdeos , vetor de expressão, célula hospedeira, composição, uso de uma variante, e, método para tratar de um mamìfero tendo uma doença ou um distúrbio em que a formação de coágulo seja desejável
US5652133A (en) Cloning and expression of the human macrophage inflammatory protein-1.alpha.α) /rantes receptor
Randall Armant Cell interactions with laminin and its proteolytic fragments during outgrowth of mouse primary trophoblast cells
ATE294236T1 (de) Promotor der tie rezeptor protein kinase
Kariya et al. Efficient expression system of human recombinant laminin-5
Kadoya et al. Laminin α1 chain G domain peptide, RKRLQVQLSIRT, inhibits epithelial branching morphogenesis of cultured embryonic mouse submandibular gland
CO5640145A2 (es) Procedimiento para la preparacion de un factor quimiotactico modificado en el n-terminal
Wang et al. Glycosylation regulates N-terminal proteolysis and activity of the chemokine CCL14
Barry et al. Hyaluronan-binding region of aggrecan from pig laryngeal cartilage. Amino acid sequence, analysis of N-linked oligosaccharides and location of the keratan sulphate
Atkins et al. Coordinate expression of OPN and associated receptors during monocyte/macrophage differentiation of HL‐60 cells

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.